Future therapeutic paradigms must therefore shift from global NF-κB inhibition toward precision rewiring of PTM-defined NF-κB circuits, enabling selective dismantling of tumor-promoting signals while preserving host immunity. This evidence concerns the gene NFKB1 and neoplasm.